BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to find the highest tolerable dose of BAY 43-9006 (sorafenib) and
bevacizumab that can be given with paclitaxel and carboplatin in patients with non-small cell
lung cancer (NSCLC). The safety and effectiveness of this drug combination will also be
studied.